Paper Details

  1. Home
  2. Paper Details

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Author: Farrerons-MinguellaJordi, HalseJohan, KrögerHeikki, MaroniMarilyn, MulderHenk, Muñoz-TorresManuel, Snorre ØfjordErik, SääfMaria, VälimäkiMatti J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study discussed the use of risedronate for the prevention and treatment of osteoporosis in postmenopausal women, highlighting the need for research on its effects in maintaining or increasing bone mineral density (BMD) in osteopenia.
Paper Details　
Original Abstract of the Article :
Randomized clinical trials have shown that risedronate reduces the risk for both ver- tebral and nonvertebral fractures in postmenopausal women with osteoporosis (bone mineral density [BMD] T-score, <-2.5). If left untreated, osteopenia (T-score, between -1 and -2.5) may progress to osteo- porosis. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2007.09.017

データ提供：米国国立医学図書館（NLM）

Osteopenia: Navigating the Desert of Bone Health

Osteopenia, a condition characterized by reduced bone density, can increase the risk of fractures and other bone-related complications. This research investigates the effectiveness of risedronate, a medication used to treat osteoporosis, in maintaining or increasing bone mineral density in postmenopausal women with osteopenia.

The authors conduct a multinational, randomized, double-blind, placebo-controlled trial, meticulously examining the impact of risedronate on bone mineral density and bone turnover markers. This study, like a caravan meticulously navigating a vast desert, seeks to understand the potential benefits of risedronate in addressing the challenges of osteopenia.

Navigating the Desert of Bone Loss: Finding a Path to Stronger Bones

The study's findings suggest that risedronate may play a role in maintaining or increasing bone mineral density in postmenopausal women with osteopenia. This discovery offers a glimmer of hope for individuals seeking to improve their bone health and reduce the risk of fractures.

A Desert of Knowledge: The Importance of Early Intervention

This research underscores the importance of early intervention in addressing bone health concerns. By recognizing osteopenia and taking proactive steps to maintain bone density, individuals may reduce their risk of developing osteoporosis and its associated complications.

Dr.Camel's Conclusion

This research provides valuable insights into the potential of risedronate in managing osteopenia. It highlights the importance of early intervention and proactive bone health management to reduce the risk of fractures and improve overall bone health. As we continue to explore the desert of bone health, this research offers a guide for finding the best path towards stronger bones and a healthier life.

Date :
  1. Date Completed 2008-01-08
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

18035193

DOI: Digital Object Identifier

10.1016/j.clinthera.2007.09.017

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.